• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000915.SZ
Share

Shandong Wit Dyne Health Co.,Ltd. Stocks

CN¥ 24.75Last Updated 13.07.2026

Issuer Rating

6/7
Performance

Excellent

Risk

Limited

Recommendation

Buy

Market Cap

CN¥ 847.97M

CN¥ 24.75
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shandong Wit Dyne Health Co., Ltd., founded on June 26, 1993, and headquartered in Jinan, China, dedicates its operations to the investigation, creation, and manufacture of pharmaceuticals and health solutions tailored for children. The company offers a wide array of products, which include vitamin A and D drops, effervescent granules containing compound calcium carbonate, licorice zinc granules, iron dextran granules, and pediatric ibuprofen suppositories. Its offerings further extend to specialized medications such as azithromycin granules, dimercaptosuccinic acid capsules, rifaximin dry suspension, and oral rehydration salt powder.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 18:05

June was TSMC's best month ever in terms of revenue. Is the AI rally continuing?

13.07.2026 17:31

"You Pay Twice for AI": Microsoft CEO Warns of Dependence on Anthropic and OpenAI

13.07.2026 16:55

Morgan Stanley Expects Earnings Growth Outside the Tech Sector. What to Buy Ahead of Earnings Season?

13.07.2026 16:34

Oninvest Index: Top AI Small-Caps for the First Half of the Year

13.07.2026 15:34

Morning in New York: External Factors Heighten Risks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026